ST 266

Drug Profile

ST 266

Alternative Names: ST-266

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Noveome
  • Developer Noveome; University of Pennsylvania
  • Class Anti-inflammatories; Growth factors; Intercellular signalling peptides and proteins; Neuroprotectants; Proteins; Small molecules
  • Mechanism of Action Paracrine communication modulators; Proto oncogene protein c akt modulators; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic conjunctivitis; Periodontitis
  • Phase I Burns; Dry eyes; Gingivitis
  • Preclinical Optic neuritis; Unspecified

Most Recent Events

  • 01 Oct 2017 Noveome completes a phase II trial in Periodontitis (Adjunctive treatment) in USA (Topical) (NCT02761993)
  • 31 Jan 2017 Preclinical trials in Optic neuritis in USA (Intranasal) before January 2017
  • 31 Jan 2017 Pharmacodynamics data from a preclinical trial in Optic neuritis released by Noveome Biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top